Target intelligence / Profile preview

Propionyl-CoA carboxylase beta chain (PCCB)

Target
PCCB
Molecular classification
Enzyme, Ligase (EC 6.4.1.3), Carboxyltransferase (as the functional domain within the beta chain)
01

Overview

Propionyl-CoA carboxylase beta chain (PCCB) is one of two essential subunits forming the mitochondrial biotin-dependent enzyme propionyl-CoA carboxylase. This multimeric complex catalyzes the ATP-dependent conversion of propionyl-CoA to D-methylmalonyl-CoA—a critical step in breaking down odd-chain fatty acids and certain amino acids. The alpha subunit provides biotin binding/carboxyation activity while the beta chain contains the catalytic site responsible for transferring CO₂ from biotin to propionyl-CoA. Mutations affecting either PCCA (alpha) or PCCB (beta) genes cause autosomal recessive disorders such as propionic acidemia, characterized by severe neonatal-onset metabolic acidosis if untreated. The only current interventions involve dietary management, cofactor supplementation with biotin when responsive, organ transplantation, or experimental gene therapies[1][2][3][4].

Other names
Propionyl-CoA carboxylase subunit betaPCCBBeta subunit of propionyl-CoA carboxylase
02

Mechanism of action

For supportive therapies: - Biotin acts as an essential cofactor required for enzymatic activity. For gene therapy or future approaches: - Gene replacement or editing to restore functional PCCB expression.

03

Biological functions

Catabolism of odd-chain fatty acidsCatabolism of branched-chain amino acids (valine, isoleucine, methionine, threonine)Conversion of propionyl-CoA to methylmalonyl-CoA in mitochondriaEnergy metabolism intermediary step for gluconeogenesis via succinyl-CoA
04

Disease associations

Inherited metabolic disease (Propionic acidemia)Other rare organic acidurias
05

Safety considerations

Loss-of-function leads to life-threatening metabolic crises due to toxic metabolite accumulation.No known safety concerns from pharmacologic inhibition because loss causes severe disease; thus, inhibition would not be therapeutically desirable.Therapeutic challenge lies primarily in restoring function rather than inhibiting it.
06

Interacting drugs

Biotin supplementation
07

Biomarkers

Elevated levels of propionic acid and related metabolites in blood/urine serve as biomarkers for loss-of-function mutations in PCCB.Genetic testing for mutations in the PCCB gene confirms diagnosis and guides patient selection/monitoring

Beyond the preview

Go deeper on Propionyl-CoA carboxylase beta chain (PCCB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Propionyl-CoA carboxylase beta chain (PCCB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call